Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma to Alopecia

One-Sentence Summary

Bimatoprost is a synthetic prostamide F2α analogue (prostaglandin analogue) originally approved for reducing intraocular pressure in open-angle glaucoma and ocular hypertension, and subsequently FDA-approved for eyelash hypotrichosis (Latisse®). The TxGNN model predicts it may be effective for alopecia (including androgenetic alopecia and alopecia areata), with 11 clinical trials and 20 publications currently supporting this direction. Evidence is at Level L2, based on multiple completed Phase 2 RCTs, supporting a “Proceed with Guardrails” recommendation.

Quick Overview

Item	Content
Original Indication	Glaucoma / Ocular hypertension; Eyelash hypotrichosis (Latisse®)
Predicted New Indication	Alopecia (Androgenetic Alopecia, Alopecia Areata)
TxGNN Prediction Score	99.99%
Evidence Level	L2
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on known pharmacological information, Bimatoprost is a synthetic prostamide F2α analogue that acts as a prostaglandin FP receptor agonist. Its efficacy in reducing intraocular pressure in glaucoma was well established first. Clinicians then observed an unexpected class effect in patients using ophthalmic prostaglandin analogues for glaucoma: hypertrichosis — increased growth and darkening of periocular lashes and brows. This serendipitous observation directly underpinned Bimatoprost’s FDA approval as Latisse® for eyelash hypotrichosis, essentially validating the same biological pathway for hair growth promotion.

Bimatoprost activates FP and EP receptors on hair follicle dermal papilla cells, stimulating Wnt/β-catenin signalling pathways that prolong the anagen (active growth) phase of the hair cycle and increase follicle size. This mechanism is directly applicable to scalp alopecia, where premature or dysregulated transition from anagen to telogen (resting) phase results in progressive hair thinning and loss. The bridge from eyelash hypotrichosis to scalp alopecia is therefore a logical anatomical and mechanistic extension — both conditions involve inadequate anagen-phase activity in hair follicles, regardless of body site.

Multiple Phase 2 RCTs in androgenetic alopecia (both male and female patterns, n > 600 combined) and prospective studies in alopecia areata provide direct clinical support. Critically, however, no Phase 3 trial has been initiated to date, strongly suggesting that Phase 2 primary efficacy endpoints likely did not demonstrate clear superiority over established treatments such as topical minoxidil or oral finasteride. The most productive deployment strategy is therefore a combination or specific sub-population approach, rather than monotherapy replacement.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01325337	Phase 2	Completed	307	Largest Phase 2 RCT in male AGA: 3 bimatoprost doses vs vehicle and minoxidil 5% OTC; double-blind except minoxidil arm
NCT01325350	Phase 2	Completed	306	Paired female counterpart: bimatoprost doses vs vehicle and minoxidil 2% OTC in women with female pattern hair loss
NCT01904721	Phase 2	Completed	244	Dedicated safety and efficacy RCT of bimatoprost in male androgenic alopecia
NCT05600673	Phase 1/2	Completed	30	CO₂ fractional laser combined with bimatoprost 0.03% for alopecia areata; novel combination approach
NCT02170662	Phase 2	Completed	33	Mechanistic study: effect of bimatoprost solution on androgen-dependent scalp hair follicles
NCT01023841	Phase 4	Completed	71	Post-marketing study in children with eyelash loss/hypotrichosis; validates safety of bimatoprost in hair loss indications across age groups
NCT01189279	Phase 1	Completed	42	Safety, tolerability, and pharmacokinetics of new bimatoprost formulation in alopecia patients; two formulations evaluated
NCT02848300	Phase 1	Completed	11	Local scalp pharmacokinetics and tolerability of bimatoprost topical formulations in male AGA over 14 days
NCT00187577	N/A	Completed	14	Latanoprost vs bimatoprost for eyelash regrowth in alopecia areata; relative efficacy comparison in periocular AA
NCT02676310	Phase 1	Terminated	53	Dose escalation safety/tolerability/PK study in male AGA; early termination may reflect development strategy change

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32250713	2022	Systematic Review with Meta-analysis	Journal of Dermatological Treatment	Network meta-analysis of non-surgical AGA monotherapies in men and women; contextualises bimatoprost’s relative efficacy ranking versus minoxidil and finasteride
28264599	2017	Narrative Review	Expert Opinion on Investigational Drugs	Dedicated review of bimatoprost for eyelash, eyebrow, and scalp alopecia; covers FP receptor mechanism, clinical trial summaries, and dermatological applications
29863806	2018	Clinical Guideline	The Journal of Dermatology	Japanese 2017 guidelines for male- and female-pattern hair loss; contextualises bimatoprost’s positioning within treatment algorithms
40252129	2025	Prospective Clinical Study	Archives of Dermatological Research	CO₂ fractional laser + bimatoprost combination for alopecia areata; demonstrates enhanced hair regrowth versus laser alone — supports combination strategy
37089845	2023	Prospective Non-Randomised Open-label	Indian Dermatology Online Journal	Bimatoprost vs clobetasol propionate in scalp alopecia areata; direct head-to-head data for a newer treatment modality
35278027	2022	Prospective Open-label Study	Dermatologic Therapy	Topical bimatoprost for eyelash loss in alopecia totalis and universalis; 16 of 19 patients achieved measurable eyelash regrowth over ~31-week treatment
29854658	2018	Review	Indian Dermatology Online Journal	Bimatoprost in dermatology: mechanism of prostaglandin-induced hypertrichosis; applications in alopecia, vitiligo, and hyperpigmentation
35040730	2022	Pharmaceutical/Formulation Study	Drug Delivery	Novel topical bimatoprost formulation achieving 4.6-fold higher human skin flux; highlights importance of formulation optimisation for scalp delivery
38577618	2024	Pharmaceutical Study	International Journal of Pharmaceutics: X	Spanlastic vesicular nanogel system for bimatoprost showing superior cutaneous deposition and hair regrowth in androgenic alopecia model; next-generation delivery platform
37185388	2023	Review	Current Oncology (Toronto)	Prevention and treatment of chemotherapy-induced alopecia; bimatoprost cited as emerging therapeutic option for CIA sub-population

South Africa Market Information

Bimatoprost is not currently registered with SAHPRA and is not marketed in South Africa. No licensed products appear in the SAHPRA database, and no Essential Medicines List (EML) status applies.

Any clinical use of bimatoprost for alopecia in South Africa would therefore require one of the following regulatory pathways:

Section 21 authorisation (unregistered medicine for a specific named patient), or
A formal SAHPRA regulatory submission for a new product registration with an alopecia indication

Prescribers should note that the ophthalmic formulations registered in other markets (Lumigan® 0.03%, Latisse® 0.03%) have not been evaluated or approved by SAHPRA for dermatological (scalp) use. Any off-label or compassionate use must be managed through appropriate regulatory channels.

Safety Considerations

Specific SAHPRA-approved prescribing information (warnings, contraindications, drug interactions) is unavailable, as bimatoprost holds no South African registration.

Please refer to the FDA-approved Prescribing Information for Lumigan® (bimatoprost ophthalmic solution 0.03%) and Latisse® as reference safety documents. Report any adverse drug reactions arising from compassionate or Section 21 use to SAHPRA via the MedSafety reporting system.

Key safety signals relevant to topical scalp use, drawn from known pharmacological class effects and trial reports:

Local tolerability: Skin irritation, erythema, pruritus, and contact dermatitis have been reported at application sites in scalp studies.
Hyperpigmentation: Prolonged prostaglandin analogue exposure can cause skin darkening — clinically relevant in patients with darker Fitzpatrick phototypes (important consideration for South African patient populations).
Ocular safety: Inadvertent eye contact should be strictly avoided; the prostaglandin mechanism can lower intraocular pressure and cause conjunctival hyperaemia.
Systemic absorption: Phase 1 scalp PK studies (NCT02848300) confirm measurable systemic absorption; caution is warranted in pregnancy (Category C) and in patients with pre-existing cardiovascular or respiratory conditions.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bimatoprost has a well-characterised, biologically plausible mechanism (FP/EP receptor-mediated anagen phase extension) that is already clinically validated by its FDA-approved eyelash hypotrichosis indication (Latisse®). Multiple completed Phase 2 RCTs in androgenetic alopecia and prospective studies in alopecia areata confirm target-organ activity in scalp follicles, placing this at Evidence Level L2. The critical guardrail is the absence of Phase 3 data, which implies the drug likely did not demonstrate clear superiority over minoxidil or finasteride monotherapy in the completed trials — and that combination or niche sub-population strategies are the more appropriate development path.

To proceed, the following is needed:

Regulatory pathway: Initiate SAHPRA Section 21 authorisation for compassionate use, or plan a full product registration submission for the alopecia indication
MOA data: Retrieve full mechanistic data from DrugBank (DB00905) to formally document the FP/EP receptor rationale in any regulatory dossier
Formulation decision: Define whether standard ophthalmic solution (0.03%) or a purpose-designed scalp formulation (enhanced permeability) will be used — evidence strongly favours optimised topical formulations for scalp delivery
Target population selection: Prioritise the sub-population with the strongest evidence base (male androgenetic alopecia, female pattern hair loss, or combination-therapy in alopecia areata) rather than a broad “alopecia” label
Phase 3 planning: Review reasons for non-progression of Phase 2 programmes (NCT01325337, NCT01325350) before committing to further investment; if efficacy shortfall vs minoxidil is confirmed, design a combination trial (bimatoprost + minoxidil) rather than monotherapy Phase 3
South Africa-specific safety monitoring plan: Include skin pigmentation monitoring protocols suitable for diverse Fitzpatrick phototype representation in the South African patient population

⚠️ YMYL Disclaimer: This report is intended for research reference purposes only and does not constitute medical advice. All drug repurposing candidates identified by TxGNN require prospective clinical validation before clinical application. Healthcare professionals should exercise independent clinical judgement and comply with applicable SAHPRA regulations.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.